Phase 1 Immune Clinical Trials
81 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 81 trials
Recruiting
Phase 1Phase 2
Controlling Hyperactive Immunity With Long-lived Lymphocytes
Rheumatoid Arthritis (RA)Autoimmune Rheumatologic DiseaseDiffuse Cutaneous Systemic Sclerosis+1 more
Quell Therapeutics Limited16 enrolled6 locationsNCT07473154
Recruiting
Phase 1
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 1
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Refractory Autoimmune Diseases
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company125 enrolled28 locationsNCT07115745
Recruiting
Phase 1
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
NeoplasmLymphoproliferative DisordersNeoplasms by Histologic Type+11 more
Kelonia Therapeutics, Inc.70 enrolled7 locationsNCT07075185
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
healthy adult participantsHealthy ParticipantsHealthy Volunteers+4 more
BeiGene211 enrolled13 locationsNCT06342713
Recruiting
Phase 1Phase 2
Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells
Autoimmune Diseases
Shenzhen Geno-Immune Medical Institute30 enrolled1 locationNCT06435897
Recruiting
Phase 1
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 1Phase 2
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Immune Thrombocytopenia (ITP)
Eli Lilly and Company58 enrolled45 locationsNCT06721013
Recruiting
Phase 1Phase 2
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Phase 1Phase 2
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Systemic Lupus ErythematosusLupusAutoimmune Disorders+2 more
M.D. Anderson Cancer Center47 enrolled2 locationsNCT06434363
Recruiting
Phase 1
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
Immune Thrombocytopenic Purpura
New York Medical College20 enrolled1 locationNCT04323748
Recruiting
Phase 1Phase 2
Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)
Viral InfectionPrimary Immune Deficiency Disorder
New York Medical College40 enrolled7 locationsNCT04197596
Recruiting
Phase 1
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting
Phase 1
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.32 enrolled9 locationsNCT06680037
Recruiting
Phase 1Phase 2
Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector
Adenosine Deaminase Severe Combined Immune Deficiency
University of California, Los Angeles20 enrolled1 locationNCT05432310
Recruiting
Phase 1Phase 2
Daratumumab in Primary Antiphospholipid Syndrome
Autoimmune Disorders
National Institute of Allergy and Infectious Diseases (NIAID)22 enrolled8 locationsNCT05671757
Recruiting
Phase 1Phase 2
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
ITPImmune Thrombocytopenia (ITP)Monoclonal+2 more
Climb Bio, Inc.24 enrolled20 locationsNCT07043946
Recruiting
Phase 1Phase 2
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
HemoglobinopathiesMetabolic DisordersHematologic, Immune, or Bone Marrow Disorders+1 more
Washington University School of Medicine220 enrolled28 locationsNCT00920972
Recruiting
Phase 1
A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.
Autoimmune Disease
Changchun GeneScience Pharmaceutical Co., Ltd.48 enrolled1 locationNCT07366866
Recruiting
Phase 1Phase 2
Immune Tolerance Induction After Liver Transplantation
Liver TransplantationEnd Stage Liver DiseaseImmune Tolerance+6 more
University of California, Los Angeles12 enrolled1 locationNCT07269041